Literature DB >> 26559735

Personal protective equipment processes and rationale for the Nebraska Biocontainment Unit during the 2014 activations for Ebola virus disease.

Elizabeth L Beam1, Shelly Schwedhelm2, Kathleen Boulter2, Christopher Kratochvil3, John Lowe4, Angela Hewlett5, Shawn G Gibbs4, Philip W Smith5.   

Abstract

In response to the Ebola virus disease outbreak of 2014, specific procedures for personal protective equipment use were developed in the Nebraska Biocontainment Unit for the isolation care of patients with the illness. This brief report describes the 2 different levels used for patient care and presents the rationales for the specialized processes.
Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ebola; Infectious disease; Isolation; Patient care; Personal protective equipment; Safety

Mesh:

Year:  2015        PMID: 26559735     DOI: 10.1016/j.ajic.2015.09.031

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  9 in total

1.  Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff.

Authors:  Jos H Verbeek; Blair Rajamaki; Sharea Ijaz; Christina Tikka; Jani H Ruotsalainen; Michael B Edmond; Riitta Sauni; F Selcen Kilinc Balci
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

2.  Determining training and education needs pertaining to highly infectious disease preparedness and response: A gap analysis survey of US emergency medical services practitioners.

Authors:  Aurora B Le; Sean A Buehler; Paul M Maniscalco; Pamela Lane; Lloyd E Rupp; Eric Ernest; Debra Von Seggern; Katherine West; Jocelyn J Herstein; Katelyn C Jelden; Elizabeth L Beam; Shawn G Gibbs; John J Lowe
Journal:  Am J Infect Control       Date:  2018-03       Impact factor: 2.918

3.  Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care.

Authors:  Joshua L Santarpia; Danielle N Rivera; Vicki L Herrera; M Jane Morwitzer; Hannah M Creager; George W Santarpia; Kevin K Crown; David M Brett-Major; Elizabeth R Schnaubelt; M Jana Broadhurst; James V Lawler; St Patrick Reid; John J Lowe
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

4.  Clinician perceptions of respiratory infection risk; a rationale for research into mask use in routine practice.

Authors:  Ruth Barratt; Ramon Z Shaban; Gwendoline L Gilbert
Journal:  Infect Dis Health       Date:  2019-02-21

Review 5.  Ebola Virus Disease: Clinical Challenges, Recognition, and Management.

Authors:  Elizabeth L Beam; Michelle M Schwedhelm; Kathleen C Boulter; Angela M Vasa; LuAnn Larson; Theodore J Cieslak; John J Lowe; Jocelyn J Herstein; Christopher J Kratochvil; Angela L Hewlett
Journal:  Nurs Clin North Am       Date:  2019-03-26       Impact factor: 1.208

6.  Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff.

Authors:  Jos H Verbeek; Blair Rajamaki; Sharea Ijaz; Riitta Sauni; Elaine Toomey; Bronagh Blackwood; Christina Tikka; Jani H Ruotsalainen; F Selcen Kilinc Balci
Journal:  Cochrane Database Syst Rev       Date:  2020-04-15

7.  Daylight-driven rechargeable antibacterial and antiviral nanofibrous membranes for bioprotective applications.

Authors:  Yang Si; Zheng Zhang; Wanrong Wu; Qiuxia Fu; Kang Huang; Nitin Nitin; Bin Ding; Gang Sun
Journal:  Sci Adv       Date:  2018-03-16       Impact factor: 14.136

8.  Call for improvement in personal protective equipment guidance and research.

Authors:  Elizabeth L Beam
Journal:  Am J Infect Control       Date:  2016-09-23       Impact factor: 2.918

9.  Catalytic inactivation of influenza virus by iron oxide nanozyme.

Authors:  Tao Qin; Ruonan Ma; Yinyan Yin; Xinyu Miao; Sujuan Chen; Kelong Fan; Juqun Xi; Qi Liu; Yunhao Gu; Yuncong Yin; Jiao Hu; Xiufan Liu; Daxin Peng; Lizeng Gao
Journal:  Theranostics       Date:  2019-09-21       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.